Adalimumab for Induction of Remission in Patients with Crohn's Disease: a Systematic Review and Meta-analysis

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2022 Sep 29

PMID 36175983

Authors

Juntao Yin

Yang Li

Yangyang Chen

Chaoyang Wang

Xiaoyong Song

Affiliations

Soon will be listed here.

Abstract

Purpose: A large number of people with Crohn's disease (CD) fail to recover from conventional therapy or biological therapy. Some studies showed that adalimumab (ADA) may be an effective alternative therapy for these patients. The aim of this study was to evaluate the efficacy and safety of ADA in inducing CD remission.

Methods: We performed search of Pubmed/MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Register, and several other databases. Randomized controlled trials (RCTs) comparing any dose of ADA with controls (placebo or active) in participants with active CD were included. The primary outcome was the failure to achieve clinical response/remission at 4 weeks. Several subgroup and sensitivity analyses were performed. Review Manager Software v5.3 was used.

Results: Four RCTs were included (n = 919), in which 553 participants received ADA and 366 participants received placebo. A meta-analysis of four studies showed that at 4 weeks, there were more people in the ADA group with clinical response/remission or symptom improvement compared with the placebo group. The rates of side effects, serious side effects, and study withdrawals due to side effects were lower in ADA participants than placebo ones.

Conclusion: This meta-analysis shows that ADA is superior to placebo in induction of clinical response/remission of CD patients, but no firm conclusions can be drawn on the safety of ADA in CD due to the low number of events.

Citing Articles

Placebo-Controlled Trials in the Management of Crohn's Disease: An Umbrella Review of Meta-Analyses.

Silva R, Azevedo J, Machado J, Rodrigues J Med Sci (Basel). 2025; 13(1).

PMID: 39982236 PMC: 11843887. DOI: 10.3390/medsci13010012.

Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems.

Di Rienzo A, Marinelli L, Dimmito M, Toto E, Di Stefano A, Cacciatore I Pharmaceutics. 2024; 16(9).

PMID: 39339221 PMC: 11435298. DOI: 10.3390/pharmaceutics16091185.

Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis.

Merza N, Nawras Y, Saab O, Dahiya D, Ahmed Z, Ranabothu M Gastroenterology Res. 2024; 16(6):289-306.

PMID: 38186583 PMC: 10769610. DOI: 10.14740/gr1664.

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease.

Vernero M, Bezzio C, Ribaldone D, Costa S, Scalvini D, Tribocco E J Clin Med. 2023; 12(21).

PMID: 37959304 PMC: 10647534. DOI: 10.3390/jcm12216839.

References

Lichtenstein G, Feagan B, Cohen R, Salzberg B, Diamond R, Price S . Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012; 107(9):1409-22. PMC: 3438468. DOI: 10.1038/ajg.2012.218. View

Papamichael K, Vajravelu R, Osterman M, Cheifetz A . Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018; 63(3):761-767. PMC: 5823777. DOI: 10.1007/s10620-018-4917-7. View

Huang M, Ran Z, Shen J, Li X, Xu X, Xiao S . Efficacy and safety of adalimumab in Crohn's disease: meta-analysis of placebo-controlled trials. J Dig Dis. 2011; 12(3):165-72. DOI: 10.1111/j.1751-2980.2011.00493.x. View

Rubin G, Hungin A, Chinn D, Dwarakanath D . Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther. 2004; 19(5):529-35. DOI: 10.1111/j.1365-2036.2004.1873.x. View

Lahat A, Lang A, Ben-Horin S . Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2011; 85(1):1-8. DOI: 10.1159/000332079. View

Beraldo R, Marcondes M, Baima J, Barros J, Ramdeen M, Saad-Hossne R . Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn's Disease?. Clin Exp Gastroenterol. 2020; 13:293-298. PMC: 7473976. DOI: 10.2147/CEG.S263685. View

Sussman D, Kubiliun N, Mulani P, Chao J, Gillis C, Yang M . Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis. 2012; 18(11):2043-55. DOI: 10.1002/ibd.22873. View

Sandborn W, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J . Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018; 48(1):65-77. PMC: 6032827. DOI: 10.1111/apt.14794. View

Terdiman J, Gruss C, Heidelbaugh J, Sultan S, Falck-Ytter Y . American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013; 145(6):1459-63. DOI: 10.1053/j.gastro.2013.10.047. View

10.

Watanabe M, Hibi T, Lomax K, Paulson S, Chao J, Alam M . Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012; 6(2):160-73. DOI: 10.1016/j.crohns.2011.07.013. View

11.

Tursi A, Angarano G, Monno L, Saracino A, Signorile F, Ricciardi A . COVID-19 infection in Crohn's disease under treatment with adalimumab. Gut. 2020; 69(7):1364-1365. DOI: 10.1136/gutjnl-2020-321240. View

12.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

13.

Hisamatsu T, Suzuki Y, Kobayashi M, Hagiwara T, Kawaberi T, Ogata H . Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study. Intest Res. 2020; 19(4):408-418. PMC: 8566837. DOI: 10.5217/ir.2020.00025. View

14.

Colombel J, Sandborn W, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P . Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2017; 47(2):219-228. DOI: 10.1111/apt.14420. View

15.

Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

16.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

17.

Plevris N, Jenkinson P, Arnott I, Jones G, Lees C . Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease. Eur J Gastroenterol Hepatol. 2019; 32(1):32-37. DOI: 10.1097/MEG.0000000000001561. View

18.

Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay J . 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2016; 11(1):3-25. DOI: 10.1093/ecco-jcc/jjw168. View

19.

Greener T, Boland K, Milgrom R, Ben-Bassat O, Steinhart A, Silverberg M . Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients. Eur J Gastroenterol Hepatol. 2021; 33(10):1274-1279. DOI: 10.1097/MEG.0000000000002250. View

20.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151(4):W65-94. DOI: 10.7326/0003-4819-151-4-200908180-00136. View